论文部分内容阅读
白血病是正常造血发育过程中某一阶段细胞恶性扩增的克隆性异质性疾病。白血病细胞群在功能上具有异质性,由白血病干细胞(LSCs)和不同分化程度的白血病细胞组成,LSCs是白血病复发的根源。LSCs细胞群数量极少,具有自我更新和增殖能力,表型特征与造血干细胞相似,LSCs表型特征为CD34+,CD38-,CD90?,CD117?,CD123+。急性髓细胞白血病的LSCs中存在核因子(NF)-кB的组成性激活以及PI3K活化等。针对LSCs的靶向治疗包括小分子抑制剂靶向抑制关键的信号转导通路(如PI3K/Akt/mTOR、NF-кB)、毒性药物结合特异性抗体靶向细胞表面分子(如CD123、CD44)等,有望最终治愈白血病。
Leukemia is a clonal heterogeneity of malignant cell proliferation in a certain stage of normal hematopoietic development. The leukemia cell population is functionally heterogeneous and consists of leukemic stem cells (LSCs) and differentiated leukemic cells. LSCs are the source of leukemia relapse. The number of LSCs cell population is very small, with self-renewal and proliferation ability. The phenotypic characteristics of LSCs are similar to that of hematopoietic stem cells. The phenotypic characteristics of LSCs are CD34 +, CD38-, CD90 ?, CD117 ?, and CD123 +. Acute myeloid leukemia in the presence of nuclear factor nuclear factor (NF) -κB constitutive activation and PI3K activation. Targeted therapies targeting LSCs include the inhibition of key signaling pathways by small molecule inhibitors (eg, PI3K / Akt / mTOR, NF-кB), toxic drug-binding specific antibodies targeting cell surface molecules (eg CD123, CD44) And so on, is expected to eventually cure leukemia.